Old name, new purpose: why we’ve gone back to RNID

Hearing Therapeutics Initiative

The Hearing Therapeutics Initiative (HTI) will accelerate the development of therapeutics to prevent and treat hearing loss and tinnitus by offering a broad range of support to innovators within academia and commercial organisations.

The Hearing Therapeutics Initiative brings together the following organisations with unique knowledge, expertise and specialised networks in hearing research, drug discovery and development: RNID, the Medicines Discovery Catapult, the National Institute for Health Research (NIHR) through its Biomedical Research Centres (BRC) with leading academic expertise in hearing research from University College London Hospitals BRC, Nottingham BRC and Manchester BRC, and the Cell and Gene Therapy Catapult.

Through the Initiative, innovators will be able to:

  • Forge links with key opinion leaders, to access know-how and expertise across hearing research topics, clinical trial design and cell and gene therapies, as well as specialist CROs and CMOs 
  • Access collaboration opportunities with HTI partners and other organisations within our extended network of industry and academic contacts, clinical trial delivery infrastructure, market intelligence and patient insight. 

Are you an innovator or investor active in, or interested in entering the hearing therapeutics space? The HTI would love to hear from you. Email us at: hti@rnid.org.uk.